NCT01227681

Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease

A Double-Blind, Placebo-Control, Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: Buddhist Tzu Chi General Hospital · Academic / Other
• Sex: All
• Age: 40 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the effectiveness of neuroprotection from granulocyte colony-stimulating factor on Parkinson disease

Detailed description

Parkinson's disease (PD) is the second most common neurodegenerative disease and the severity of PD still progress during the ensuing years. Currently, there is no promising medical or surgical treatment to abrogate the disease deterioration. Granulocyte colony-stimulating factor (G-CSF), one of hematopoietic growth factors, has been routinely used for hematologic disorders and stem cell harvest from normal subject. G-CSF also demonstrated neuroprotection for rodents PD model. We hypothesize G-CSF will exert the effectiveness of neuroprotection for PD patients.

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	G-CSF	G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously
DRUG	Placebo	Sodium Chloride (NaCl) 0.9 %

Timeline

• Start date: 2010-06-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2010-10-25
• Last updated: 2016-04-04
• Results posted: 2016-04-04

Locations

1 site across 1 country: Taiwan